IRF4抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P07389(IRF4 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P07389(IRF4 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The interferon regulatory factor 4 (IRF4) antibody is a crucial tool for studying the role of IRF4. a transcription factor belonging to the IRF family. IRF4 is primarily expressed in immune cells, including B cells, T cells, and plasma cells, where it regulates lymphocyte development, differentiation, and immune response modulation. It binds to DNA either alone or in complexes with other transcription factors (e.g., PU.1) to control genes involved in apoptosis, proliferation, and cytokine signaling. Dysregulation of IRF4 is implicated in pathologies such as lymphoid malignancies (e.g., multiple myeloma, diffuse large B-cell lymphoma), autoimmune diseases, and melanoma.

IRF4 antibodies are widely used in research to detect IRF4 expression via techniques like Western blotting, immunohistochemistry (IHC), and flow cytometry. They help identify IRF4’s involvement in oncogenesis, particularly its overexpression in certain cancers, and its role in maintaining plasma cell identity. Clinically, IRF4 antibodies aid in diagnosing IRF4-driven large B-cell lymphoma and monitoring disease progression. Recent studies also explore IRF4 as a potential therapeutic target, given its dual role as both a tumor suppressor and promoter in different contexts. However, challenges remain in understanding its context-dependent mechanisms and therapeutic applicability.